GSK Stock DD GlaxoSmithKline plc 08/27/2014 18:26:58

New Post Public Reply Private Reply Replies (0) Message Board

Aug 27, 2014 at 7:27 PM

GSK GlaxoSmithKline plc $GSK Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=GSK&...mp;yt0=Go!

Last Updated: 08/27/2014 18:26:54

Current Price and Quotes
Last Price
Previous Close Open
Daily Range - 52wk Range -
Volume Dividend
Average Vol (30d) Yield

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 43,899,000 42,964,000 42,563,000 44,452,000
Cost of Revenue 14,219,000 12,882,000 11,925,000 12,366,000
Gross Profit 29,680,000 30,082,000 30,638,000 32,087,000
Operating Expenses

Research and Development 6,498,000 6,468,000 6,248,000 6,978,000
Sales, General and Admin. 11,542,000 11,748,000 12,371,000 19,185,000
Non-Recurring Items - - - -
Other - - - -
Operating Income 11,640,000 11,866,000 12,020,000 5,923,000
Income From Continuing Operations

Add'l Income/Expense Items 568,000 128,000 1,049,000 195,000
Earnings Before Interest and Tax 12,279,000 12,041,000 13,092,000 6,244,000
Interest Expense 1,270,000 1,313,000 1,242,000 1,301,000
Earnings Before Tax 11,009,000 10,728,000 11,850,000 4,943,000
Income Tax 1,688,000 3,124,000 3,450,000 2,042,000
Minority Interest 318,000 291,000 306,000 343,000
Equity Earnings Unconsolidated Subsidiary 71,000 47,000 23,000 127,000
Net Income Cont. Operations 9,075,000 7,360,000 8,117,000 2,685,000
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 9,003,000 7,313,000 8,094,000 2,558,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 9,003,000 7,313,000 8,094,000 2,558,000

Recent News

Aug 27, 2014 Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia
Aug 26, 2014 GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)
Aug 26, 2014 Ethical Pharmaceuticals Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Aug 26, 2014 GlaxoSmithKline/Theravance's Anoro Ellipta is Most Likely to Replace Boehringer Ingelheim's Spiriva Among COPD Patients, According to U.S. Pulmonologists
Aug 26, 2014 Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis
Aug 26, 2014 The Zacks Analyst Blog Highlights: GlaxoSmithKline, Pfizer, Johnson & Johnson, Allergan and EA Sports
Aug 25, 2014 Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
Aug 25, 2014 Clinical Trial Results, Change of Corporate Name, New Products, and Completion of Acquisition - Research Reports on GSK, Amicus, WellPoint, IDEXX and Endo
Aug 22, 2014 ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
Aug 21, 2014 Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms

1
2
3
4
5
6
7
8
next >
last >>

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EQT Acquires Range Resources: Redefining Gas Markets

A New Chapter in Natural Gas Who would have thought? EQT Corporation, that sturdy old veteran in the natural gas game, finally made its move and snatched up Range Resources, sprinting right out of left field. This merger isn't just about two companies shaking hands; it's about rewriting the entire narrative of America's natural gas landscape. With this acquisition, EQT's...

Ericsson Executes Bold Share Buyback Plan in Oct.

Ericsson Kicks Off October with Major Share Repurchases Ericsson's taking bold steps in consolidating shareholder value, and folks, this ain't your run-of-the-mill stock-in-the-drawer move. Between October 19 and 23, 2026, Ericsson picked up 500,000 of its own Class B shares. Yep, you heard right—half a million shares just like that, with a neat price tag rounding out...

WuXi AppTec Boosts Guidance Amid Strong CRDMO Growth

Unpacking WuXi AppTec's Latest Performance Boost WuXi AppTec, the pharmaceutical giant, isn't just coasting on its past successes. The way they're riding the contract research, development, and manufacturing (CRDMO) train straight through Q1 to Q3 of 2026 shows they're not just here for show. They've hiked up the stakes with strong metrics across the board, warranting a...

Shenzhen Hosts FDI Moot: A Key Milestone for Arbitration

Shenzhen Steps into the Arbitration Spotlight In a move that's bound to tweak some eyebrows in the legal realm, Shenzhen just hosted the 2026 Foreign Direct Investment International Arbitration Moot (FDI Moot) Global Finals. This marks the first time the finals have landed on Chinese soil, and folks, that's a big deal. It’s a hefty nod to China's expanding credibility...

Metallium's U.S. Supply Chain Ambitions Hinge on Traxys MOU

Metallium and Traxys Partner to Boost U.S. Critical Metals Out there in Houston, October's cooked up a potential game-changer for U.S. critical metals supply like no one's business. Metallium Limited—those savvy cats juggling ASX and OTC markets—just laid down a non-binding Memorandum of Understanding (MOU) with Traxys North America LLC. The goal? To sharpen up and...

GrOwnValve's Personalized Valves Pass Safety Milestone

Pioneering Success in Personalized Valve Study GrOwnValve GmbH just hit a big milestone that's caught my attention. Their first-in-human heart valve study wrapped up its six-month run with no prosthesis-related mishaps. Yeah, zero misfires. For five whole patients who've been through the wringer, things held steady. This Berlin startup’s got guts, testing tech that...

Duke Energy's Battle Against Energy Vampires Heats Up

Unplugging Hidden Electricity Drains Ever wonder why your electric bill has been sneakily creeping up? You might think it's just the AC running full blast or lights left on, but surprise, surprise—there’s a whole army of “energy vampires” quietly sucking the juice out of your home. Duke Energy Florida is drawing attention to this sneaky leak, especially around...

New Drug Revolutionizes Endometrial Cancer Treatment

A New Dawn for Endometrial Cancer Treatment Alright, every once in a while, something shakes up the world of oncology. And that's exactly what's happening with sacituzumab tirumotecan, or sac-TMT if you want to save your breath. This new drug is stepping up as a future star in the fight against endometrial cancer, according to an eye-popping international study led by NYU...

FL Technics Indonesia Expands with EASA Certification

Bali's Skies Just Got a Major Upgrade Picture this: You've got a sprawling 17,000 square meter facility sitting pretty at I Gusti Ngurah Rai International Airport, nestled in the paradise locale of Bali. What's next? It's now flexing some serious muscles with its newfound EASA Part-145 certification, allowing it to tackle aircraft registered in the European Union. This is...

Approved Oil Secures Long-Term NYC Fuel Terminal Deal

Approved Oil Locks in Future with Sunoco Deal Amidst the contraction of New York City's fuel terminal landscape, securing a consistent lifeline to crucial infrastructure feels like striking gold. Approved Oil just locked down an agreement with Sunoco for a new terminal location that'll last deep into the 2040s, and it's about more than just securing a spot on the...